Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.81 USD | +0.56% | +5.85% | -19.56% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 433.3 | 436.6 | 152.6 | 123.5 | - | - |
Enterprise Value (EV) 1 | 433.3 | 206.3 | 156.9 | 150.1 | 93.8 | 42.34 |
P/E ratio | -5.53 x | -2.85 x | -1.29 x | -1.16 x | -1.3 x | -1.43 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 86.5 x | 12.4 x |
EV / Revenue | - | - | - | - | 65.7 x | 4.23 x |
EV / EBITDA | - | -2.27 x | -1.28 x | -1.24 x | -0.62 x | -0.22 x |
EV / FCF | -5.93 x | -2.2 x | -1.55 x | -1.25 x | -0.84 x | -1.41 x |
FCF Yield | -16.9% | -45.4% | -64.6% | -80.1% | -120% | -71.1% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 37,290 | 65,649 | 67,806 | 68,260 | - | - |
Reference price 2 | 11.62 | 6.650 | 2.250 | 1.810 | 1.810 | 1.810 |
Announcement Date | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 1.429 | 10 |
EBITDA 1 | - | - | - | -90.89 | -122.5 | -121.3 | -150.8 | -189.7 |
EBIT 1 | -10.42 | -43.37 | -69.02 | -93.42 | -126 | -119.6 | -126.9 | -123.4 |
Operating Margin | - | - | - | - | - | - | -8,879.89% | -1,234.47% |
Earnings before Tax (EBT) 1 | - | -43.34 | -68.9 | -92.09 | -117.9 | -113.4 | -119.3 | -123.5 |
Net income 1 | - | -49.26 | -70.13 | -92.09 | -117.9 | -113.4 | -119.3 | -123.5 |
Net margin | - | - | - | - | - | - | -8,347.72% | -1,234.68% |
EPS 2 | -109.8 | -230.6 | -2.100 | -2.330 | -1.750 | -1.555 | -1.396 | -1.266 |
Free Cash Flow 1 | - | - | -73.04 | -93.61 | -101.4 | -120.3 | -112.2 | -30.11 |
FCF margin | - | - | - | - | - | - | -7,856.74% | -301.09% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 11/6/20 | 3/25/21 | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.31 | -22.8 | -21.79 | -24.1 | -24.72 | -30.42 | -32.17 | -35.32 | -28.12 | -32.33 | -28.5 | -27.95 | -28 | -26.79 | -28.96 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -18.25 | -22.74 | -21.66 | -23.79 | -23.91 | -28.43 | -29.98 | -33.19 | -26.26 | -30.8 | -27.26 | -26.62 | -26.57 | -26.03 | -28.2 |
Net income 1 | -18.25 | -22.74 | -21.66 | -23.79 | -23.91 | -28.43 | -29.98 | -33.19 | -26.26 | -30.8 | -27.26 | -26.62 | -26.57 | -26.03 | -28.2 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4900 | -0.6100 | -0.5800 | -0.6300 | -0.5300 | -0.4300 | -0.4500 | -0.4900 | -0.3900 | -0.4500 | -0.4069 | -0.3800 | -0.3466 | -0.3300 | -0.3380 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/14/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/7/23 | 3/20/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 4.3 | 26.6 | - | - |
Net Cash position 1 | - | - | 230 | - | - | 29.8 | 81.2 |
Leverage (Debt/EBITDA) | - | - | - | -0.0351 x | -0.219 x | - | - |
Free Cash Flow 1 | - | -73 | -93.6 | -101 | -120 | -112 | -30.1 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | 4.16 | 3.89 | 8.46 | 1.07 | 4.66 | 4.52 | 5.06 |
Capex / Sales | - | - | - | - | - | 316.19% | 50.58% |
Announcement Date | 3/25/21 | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.56% | 124M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- VOR Stock
- Financials Vor Biopharma Inc.